Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
Allogeneic stem cell transplantation is potential curative therapy for adult lymphoid
malignancies. Based on our previous study, the condition with iv-busulfan (iv-BU) and
cyclophosphamide (CTX) is feasible with low toxicity and transplantation mortality and
long-term survival is comparable to most data reported with slightly higher relapse rate
particularly for patients in CR2. In this study, the investigators aim to further improve the
conditioning with Fludarabine + iv-BU and to use CTX after stem cell transfusion as
consolidation for lymphoid malignancies and graft-versus-host disease (GVHD) prophylaxis.